Skip to main content
main-content

Diabetes medications

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews editor's pick

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

New Content Item

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

medwireNews editor's pick

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Heartbeat

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

medwireNews editor's pick

Insulin manipulation strongly linked to psychiatric comorbidity

Insulin pen

Insulin manipulation, the practice of deliberately under- or overdosing insulin, is strongly associated with psychiatric comorbidity in children and young adults with type 1 diabetes, Austrian research shows.

medwireNews editor's pick

EASE: Add-on empagliflozin improves glycemic control in type 1 diabetes

Pills

The addition of empagliflozin to insulin therapy reduces glycated hemoglobin levels in patients with type 1 diabetes, indicate findings from the phase III EASE-2 and 3 trials.

medwireNews editor’s pick

Promising phase II data for dual GIP and GLP-1 receptor agonist

Subcutaneous injection_arm

A compound that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 has dose-dependent effects on glucose levels and bodyweight in people with type 2 diabetes.

medwireNews editor's pick

Lixisenatide may lessen albuminuria progression in type 2 diabetes

Kidneys

Macroalbuminuric patients with type 2 diabetes and a recent acute coronary event who are treated with lixisenatide may experience a reduction in their urinary albumin-to-creatinine ratio, suggests an exploratory post-hoc analysis of the ELIXA trial.

medwireNews editor’s pick

Albiglutide reduces cardiovascular risk in patients with type 2 diabetes

Heart and ECG_Fotolia_287046_Subscription_XL

Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.

View from the clinic

Four steps I take when starting patients on insulin

Steps

Editorial Board member Jay Shubrook succinctly delivers his strategies for initiating insulin therapy for the first time in patients with type 2 diabetes [read more].

Get more on: Insulin | Type 2 diabetes | Psychosocial care

View from the clinic

Regaining sexual health in diabetes: Start with open communication

Worried senior man sits on bed (symbolic image with models)

Advisory Board member Clipper Young recounts an experience of starting a patient with erectile dysfunction on the path to appropriate treatment for him and his diabetes [read more].

Get more on: Diabetic complications | Psychosocial care | View from the clinic

medwireNews editor's pick

Targeting pathophysiology from outset may slow progression to type 2 diabetes

Pills_two types

Upfront treatment with medications that target the underlying pathophysiology of prediabetes may slow patients’ progression to type 2 diabetes, report researchers.

11-10-2018 | SGLT2 inhibitors | At a glance | Article

Round-up of the SGLT2 inhibitor CV outcome trials

With DECLARE-TIMI 58 now published, medwireNews rounds up the SGLT2 inhibitor cardiovascular outcome trials so far.

09-30-2018 | UKPDS | At a glance | Article

What we learned from the UKPDS

The UKPDS has so far generated an astonishing 93 original research papers. medwireNews​​​​​​​ rounds them up.

09-30-2018 | UKPDS | Feature | Article

The UKPDS: A lasting legacy

Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

11-03-2018 | Liraglutide (T2DM) | Article

Liraglutide and glycemic outcomes in the LEADER trial

Zinman B et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0524-z

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

image credits